Sleep medicine providers can help their patients by submitting appeals to insurance companies, citing information on FDA approval and Centers for Medicare & Medicaid Services proposed rulemaking regarding tirzepatide
Obesity 33(3):452462 Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S et al (2023) Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Other notable side effects include injection site reactions (redness, itching, or swelling at the injection site), fatigue, and hypoglycemia, particularly when tirzepatide is used in combination with insulin or sulfonylureas
Eligibility requirements include commercial (private) health insurance that covers Mounjaro, prescription for an FDA-approved use (type 2 diabetes), and valid HIPAA authorization